An estimated 15,000 new cases of myelodysplastic syndrome (MDS) are being diagnosed annually in the United States alone. The average age at diagnosis is about 70 years. Forty percent to 50% of patients die with infections or hemorrhage due to peripheral blood cytopenias; others develop acute leukemia. While hemopoietic stem cell transplantation offers potentially curative therapy, only a small proportion of patients are currently eligible. Additional therapeutic strategies are needed. Recent investigations have focused on the pathophysiology of MDS in an attempt to identify therapeutic targets, and several leads are promising. To further improve treatment success, studies are needed that show correlations between patient and disease characteristics on one hand and response to a given therapeutic strategy on the other. We showed in a pilot study that treatment with antithymocyte globulin (ATG) to inactivate autoreactive T cells, plus etanercept (a soluble TNFa receptor) to protect normal hematopoiesis, provides effective therapy for a subpopulation of patients. The present Phase II protocol is aimed at substantiating those findings and at correlating responses with the function of autologous T cells and specific responses to TNFa. The study will enroll patients with low or intermediate-1 risk MDS (by the International Prognostic Scoring System (IPSS).
Specific Aim 1 is to determine the rate of sustained responses to treatment with ATG and etanercept and to identify patient characteristics that correlate with responses.
Specific Aim 2 is to identify disease parameters and in vitro characteristics of marrow cells from patients with MDS, which correlate with disease course and response to therapy, with the objective of applying that information to the design of future more specific therapeutic interventions. Specifically, we will characterize marrow cells before and after therapy by multiparameter flow analysis, we will determine WT1 expression, we will assess the T-cell repertoire and CDS anti-WT1 reactivity before and after therapy, and we will determine whether there is a correlation between the presence of the HLA-DR15(01) allele, MHC class II restricted T-cell (CD4) responses, and TNFa effects. These studies are expected to improve our understanding of the pathophysiological features of MDS that are amenable to therapy with immunosuppression with ATG and modulation of TNF-mediated signals. The studies are also likely to provide further insights into the role of WT1 in marrow failure in patients with MDS and thereby establish a basis for antigen-directed therapy. Overall, the trial is expected to more clearly define the role of combination therapy with ATG and etanercept in low grade MDS, and to identify disease characteristics that can be exploited for the development of new treatment strategies. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA119599-01
Application #
7056452
Study Section
Clinical Oncology Study Section (CONC)
Program Officer
Wu, Roy S
Project Start
2005-12-06
Project End
2007-11-30
Budget Start
2005-12-06
Budget End
2006-11-30
Support Year
1
Fiscal Year
2006
Total Cost
$276,368
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Scott, Bart L; Ramakrishnan, Aravind; Fosdal, Mark et al. (2010) Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study. Br J Haematol 149:706-10
Campregher, Paulo V; Srivastava, Santosh K; Deeg, H Joachim et al. (2010) Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome. Exp Hematol 38:202-12
Marcondes, Mario; Deeg, H Joachim (2008) Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom? Best Pract Res Clin Haematol 21:67-77
Seal, Sudeshna; Hockenbery, David M; Spaulding, Emily Y et al. (2008) Differential responses of FLIPLong and FLIPShort-overexpressing human myeloid leukemia cells to TNF-alpha and TRAIL-initiated apoptotic signals. Exp Hematol 36:1660-72
Kerbauy, Daniella B; Deeg, H Joachim (2007) Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol 35:1739-46
Ying, Shao Xu; Seal, Sudeshna; Abbassi, Nissa et al. (2007) Differential effects of bexarotene on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid leukemia cell lines. Leuk Lymphoma 48:1003-14